Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma
出版年份 2021 全文链接
标题
Post treatment NLR is a predictor of response to immune checkpoint inhibitor therapy in patients with esophageal squamous cell carcinoma
作者
关键词
-
出版物
Cancer Cell International
Volume 21, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-07-07
DOI
10.1186/s12935-021-02072-x
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- High lymphocyte population-related predictive factors for a long-term response in non-small cell lung cancer patients treated with pemetrexed: a retrospective observational study
- (2021) Issei Sumiyoshi et al. Journal of Translational Medicine
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neutrophil dynamics in the tumor microenvironment
- (2021) Amanda J. McFarlane et al. JOURNAL OF CLINICAL INVESTIGATION
- Advances in immunotherapy for pancreatic ductal adenocarcinoma
- (2021) Motoki Miyazawa et al. Journal of Hepato-Biliary-Pancreatic Sciences
- Blood tests predict the therapeutic prognosis of anti‐PD‐1 in advanced biliary tract cancer
- (2021) Fei Du et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
- (2021) Nancy Y Lee et al. LANCET ONCOLOGY
- Anti-PD-1/PD-L1 Based Combination Immunotherapy to Boost Antigen-Specific CD8+ T Cell Response in Hepatocellular Carcinoma
- (2021) Julia Peña-Asensio et al. Cancers
- The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)—Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab
- (2021) Francesca Ligorio et al. Cancers
- Inflammatory Markers Predict Survival in Patients With Advanced Gastric and Colorectal Cancers Receiving Anti–PD-1 Therapy
- (2021) Xiaona Fan et al. Frontiers in Cell and Developmental Biology
- Immune-inflammatory biomarkers as prognostic factors for immunotherapy in pretreated advanced urinary tract cancer patients: an analysis of the Italian SAUL cohort
- (2021) G. Fornarini et al. ESMO Open
- Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study
- (2020) Alessandro Russo et al. ADVANCES IN THERAPY
- Prognostic role of pretreatment blood lymphocyte count in patients with solid tumors: a systematic review and meta-analysis
- (2020) Jiawen Zhao et al. Cancer Cell International
- Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study
- (2020) Jing Huang et al. LANCET ONCOLOGY
- Predictive value of neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in advanced hepatocellular carcinoma patients treated with anti–PD‐1 therapy
- (2020) Sirish Dharmapuri et al. Cancer Medicine
- Serum neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prognosticating immunotherapy efficacy
- (2020) Adi Kartolo et al. Immunotherapy
- Post-treatment neutrophil-to-lymphocyte ratio (NLR) predicts response to anti-PD-1/PD-L1 antibody in SCLC patients at early phase
- (2020) Qi Xiong et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Monocyte and T Cell Immune Phenotypic Profiles Associated With Age Advancement Differ Between People With HIV, Lifestyle-Comparable Controls and Blood Donors
- (2020) Davide De Francesco et al. Frontiers in Immunology
- Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody
- (2020) Mehmet Akce et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Elevated platelet-to-lymphocyte corresponds with poor outcome in patients with advanced cancer receiving anti-PD-1 therapy
- (2019) Yalong Qi et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
- (2019) Ken Kato et al. LANCET ONCOLOGY
- Prognostic value of the pretreatment systemic immune-inflammation index (SII) in patients with non-small cell lung cancer: a meta-analysis
- (2019) Yan Wang et al. Annals of Translational Medicine
- High neutrophil‐to‐lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD‐1 inhibitor monotherapy
- (2019) Edmund K. Bartlett et al. CANCER
- Role of the complement system in the tumor microenvironment
- (2019) Ronghua Zhang et al. Cancer Cell International
- Neutrophil-to-lymphocyte ratio as an early marker of outcomes in patients with advanced non-small-cell lung cancer treated with nivolumab
- (2018) Aya Nakaya et al. International Journal of Clinical Oncology
- Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel
- (2018) Alessandro Russo et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis
- (2018) Danielle Benedict Sacdalan et al. OncoTargets and Therapy
- Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
- (2018) Aly-Khan A. Lalani et al. Journal for ImmunoTherapy of Cancer
- Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer
- (2018) Katsutoshi Sekine et al. LUNG CANCER
- Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial
- (2017) Toshihiro Kudo et al. LANCET ONCOLOGY
- Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab
- (2017) Stefan Diem et al. LUNG CANCER
- Esophageal cancer: The latest on chemoprevention and state of the art therapies
- (2016) Gregoire F. Le Bras et al. PHARMACOLOGICAL RESEARCH
- Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
- (2015) P F Ferrucci et al. BRITISH JOURNAL OF CANCER
- Recent Advances From Basic and Clinical Studies of Esophageal Squamous Cell Carcinoma
- (2015) Shinya Ohashi et al. GASTROENTEROLOGY
- Multifunctional receptor-targeting antibodies for cancer therapy
- (2015) Yanni Zhu et al. LANCET ONCOLOGY
- Prognostic value of preoperative platelet-lymphocyte and neutrophil-lymphocyte ratio in patients undergoing surgery for esophageal squamous cell cancer
- (2014) X. Xie et al. DISEASES OF THE ESOPHAGUS
- Esophageal Carcinoma
- (2014) Anil K. Rustgi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The systemic inflammation-based neutrophil–lymphocyte ratio: Experience in patients with cancer
- (2013) Graeme J.K. Guthrie et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Role of the Microenvironment in the Pathogenesis and Treatment of Hepatocellular Carcinoma
- (2013) Virginia Hernandez–Gea et al. GASTROENTEROLOGY
- Oesophageal carcinoma
- (2013) Arjun Pennathur et al. LANCET
- The quest to overcome resistance to EGFR-targeted therapies in cancer
- (2013) Curtis R Chong et al. NATURE MEDICINE
- Cancer-related inflammation
- (2008) Alberto Mantovani et al. NATURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search